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teatosis and
iastolic Dysfunction
he Skinny on Myocardial Fat*
ason B. Lindsey, MD,
teven P. Marso, MD, FACC
ansas City, Missouri
iabetes mellitus (DM) has long been recognized as a risk
actor for cardiovascular disease including coronary artery
isease (CAD) and heart failure (HF) (1). Three decades
go, Rubler et al. (2) first described a cohort of diabetic
atients with HF but normal coronary arteries, later termed
diabetic cardiomyopathy.” Diabetic cardiomyopathy
DCM) can be defined as ventricular dysfunction that is
resent independent of CAD and hypertension (3). The
xistence of DCM is supported by population-based studies
4) and by observations that in comparison with age-
atched individuals, diabetic subjects have an increased
requency of HF that persists even after adjustment for
AD (1). Although many advocate DCM as a clinical
henotype, there is no specific mention of it in the most
ecent American College of Cardiology/American Heart
ssociation heart failure guidelines (5), and there are no
stablished criteria for its diagnosis. However, the fact
emains that those with DM have an increased risk for
evelopment of HF and a worse prognosis from HF
ompared with those without DM, yet controversy remains
s to the pathobiologic mechanisms that contribute to the
bserved myocardial dysfunction (3).
See page 1793
Myriad hypotheses have been proposed to explain the
athophysiologic derangements that may lead to myocardial
ysfunction in those with DM (3). Candidate mechanisms
nclude altered myocardial calcium homeostasis, mitochon-
rial dysfunction, oxidative stress, direct glucotoxicity, myo-
ardial fibrosis, perturbed myocardial substrate use, and
yocardial lipid accumulation (4). All are biologically plau-
ible and most are supported by animal models. Much
ecent attention has focused on the role of myocardial
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or thei
merican College of Cardiology.
From the Mid America Heart Institute, Kansas City, Missouri.teatosis in diabetic myocardial dysfunction (6). During
ormal physiologic conditions, a normal cardiomyocyte
enerates 70% of its adenosine triphosphate (ATP) from the
xidation of fatty acids (FAs). In patients with DM, glucose
ptake, glycolysis, and insulin function are deranged, result-
ng in enhanced lipolysis and release of FAs from adipose
issue. Excess myocardial FAs, which remain after cardio-
yocyte energy production, are sequestered as triglycerides
TGs) to provide cardiomyocytes a reserve of FAs. In the
ormal heart, lipolysis and lipogenesis are balanced, result-
ng in constant levels of intracellular TGs. Under conditions
f excess FA production, such as in obesity or DM, the
alance is in favor of excess intracellular TG accumulation.
he hypothesis of myocardial TG accumulation has been
upported by animal models that disrupt normal myocardial
ipid metabolism via several pathways and result in TG
ccumulation and diastolic dysfunction (7). In humans,
here are emerging yet limited data for myocardial lipid
ccumulation. For example, histopathology of explanted
earts among diabetic transplant recipients has shown
yocardial lipid accumulation (8). Recently, using magnetic
esonance spectroscopy (MRS), McGavock et al. (6) pro-
ided provocative evidence that, indeed, myocardial lipid
ccumulation occurs in vivo in humans, specifically among
ndividuals with DM and in those with insulin resistance.
In this issue of the Journal, Rijzewijk et al. (9) provide
urther compelling evidence that myocardial lipid accumu-
ation occurs in diabetic subjects and that it is independently
ssociated with impaired left ventricular (LV) diastolic
unction. The study consisted of 38 male diabetic subjects
nd 28 age- and body mass index (BMI)-comparable
ontrols. Overall, subjects had uncomplicated DM; all had
emoglobin A1c values 8.5%, with no evidence of cardio-
ascular disease or microvascular complications. Impor-
antly, the authors excluded those taking lipid-lowering
herapies and those with evidence of myocardial ischemia
as detected by dobutamine stress echocardiography). The
nvestigators then performed proton MRS on all subjects
sing a previously validated protocol, similar to the MRS
ethods used by McGavock et al (6). MRS allows for in
ivo quantification of myocardial TG content by the gen-
ration of distinct spectral peaks (corresponding to protons
n lipids), which are easily separated from the spectral peaks
f water and other tissue metabolites. Myocardial TG
ontent was then expressed as a percentage relative to
yocardial water content.
Compared with controls, those with DM had signifi-
antly higher myocardial TG content. After adjustment for
he presence of DM, myocardial TG content correlated
ith glucose concentrations, visceral adiposity, and hepatic
G content; however, plasma TG levels did not correlate
ith myocardial TG content.
In an effort to evaluate myocardial function in both
roups, the authors used several magnetic resonance imag-
ng indexes of diastolic function including the ratio of
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trial peak filling rate (E/A) and E peak deceleration.
terative multivariable analysis using E/A and E peak
eceleration as the outcome variables demonstrated that
yocardial TG content was associated with these parame-
ers of diastolic function.
Rijzewijk et al. (9) should be complimented on this
mportant contribution, which expands the findings of
cGavock et al. (6) and supports the concept of cardiac
ipotoxicity. However, certain limitations to the present
tudy should be considered. There is controversy as to the
ost valid qualitative or quantitative magnetic resonance
maging measures of diastolic function. In the current study
ome (such as E/A and E peak deceleration time), but not
ll, indexes of diastolic function were abnormal. Impor-
antly, estimations of LV filling pressures (E/Ea) were not
bnormal. These discrepancies highlight the difficulty in
uantifying diastolic function. Validation by measurement
f echocardiographic indexes of diastolic function or the use
f myocardial tagging techniques with magnetic resonance
maging would have strengthened the current observations
nd could have been performed concurrently. Although the
resence of diastolic dysfunction is a risk factor for devel-
ping diastolic HF, the presence of asymptomatic diastolic
ysfunction should not be equated with the presence of DCM.
In this study, properly accounting for the effect of obesity
n the exposure or the outcome variables is important. The
uthors attempted to adjust for the influence of obesity on
yocardial TG content by using controls and diabetic
ubjects with comparable BMI. Although subjects were
imilar by 1 parameter, BMI, the striking difference be-
ween the groups in visceral adiposity cannot be discounted.
ndeed, visceral fat correlated with myocardial TG content
nd BMI did not. In the models for diastolic function,
isceral adiposity was independently associated with dia-
tolic dysfunction but DM was not an important determi-
ant. In total, this allows for some observations: 1) the
resence of central adiposity may be more important than
M in determining myocardial TG content; and 2) mea-
ures of central adiposity (waist/hip ratio) could serve as an
nexpensive and indirect surrogate of myocardial TG con-
ent. Importantly, these hypotheses are reinforced by the
bservation of McGavock et al. (6) that visceral fat content
as the only independent determinant of myocardial TG
ontent.
There is evidence from another chronic disease state that
uggests visceral adiposity rather than diabetes per se is the
mportant determinant of intramyocellular lipid accumula-
ion. Compared with age-matched controls, nondiabetic
uman immunodeficiency virus (HIV)-lipodystrophy sub-
ects had significantly increased skeletal TG content (10).
hose with HIV-lipodystrophy had the same BMI as
ontrols but had increased central adiposity and insulin
esistance. An independent association between indexes of
entral adiposity and skeletal TG content was observed.
gain, this emphasizes the importance of fat redistribution rnd insulin resistance in the process of intramyocellular TG
ccumulation, which appears to exist even in the absence of
M. Rijzewijk et al. (9) do not report the prevalence of
nsulin resistance in the DM subjects but, based on insulin
evels, we estimate that a majority of these subjects had
nsulin resistance.
The findings from the current study suggest that myo-
ardial TG accumulation only partially explains the ob-
erved diastolic dysfunction. Evaluation of the multivariable
odels reveals that although myocardial TG content was
ssociated with diastolic dysfunction, the r2 of model #6 was
nly 0.47 and the individual contribution of myocardial TG
ontent was modest. This suggests there are other unmea-
ured variables that contribute to diastolic dysfunction.
lso, the correlation analysis between E/A and E peak
eceleration and myocardial TG content show that myo-
ardial TG content is a poor predictor of diastolic function.
urthermore, it is intriguing that a seemingly insignificant
yocardial TG content of 1% (absolute difference com-
ared with controls of 0.3%) would result in or explain the
bserved diastolic dysfunction in this study. It should be
onsidered that cardiac lipotoxicity could simply be a by-
roduct of other pathologic processes that coexist in the
iabetic heart, and processes such as altered myocardial
alcium homeostasis or myocardial fibrosis may play as
mportant a role as cardiac lipotoxicity in the development
f DCM (3).
The authors should be commended for their attempt to
xclude individuals with myocardial ischemia by screening
ith dobutamine stress echocardiography (DSE). However,
he negative predictive value of DSE is around 60% to 86%
11). Therefore, it is conceivable that some subjects may
ave had obstructive epicardial CAD. Also DSE does not
eliably evaluate microvascular coronary disease that has
een associated with diastolic dysfunction (12).
Due to the observational study design, the authors are
orrect in asserting that no conclusions about causality
hould be drawn from this study. The observation that
yocardial TG content is associated with diastolic dysfunc-
ion, although important, does not imply cause and effect.
uture study should focus on individuals with the clinical
yndrome of diabetic cardiomyopathy to better determine
he implications of the current findings.
The widespread clinical use of MRS is unlikely given the
echnical challenges involved in data acquisition, and the
recision required in measuring myocardial steatosis is not
nsignificant given the observed 1% myocardial TG con-
ent reported by Rijzewijk et al. (9) andMcGavock et al. (6).
owever, this study confirms that MRS will be a valuable
esearch tool in understanding the cardiac pathology in-
olved in obesity, insulin resistance, metabolic syndrome,
nd DM.
Is myocardial steatosis a modifiable condition? Adminis-
ration of pioglitazone, a peroxisome proliferator-activated
eceptor-gamma agonist, to diabetic subjects resulted in a
eduction of both myocardial and hepatic TG content (13).
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Steatosis and Diastolic Dysfunction November 25, 2008:1800–2ue to the observed relationship between central adiposity
nd myocardial TG content, it can be postulated that
ifestyle modification through exercise and weight reduction
trategies could result in a reduction of myocardial TG
ontent. This is a hypothesis that can and should be tested
n future studies evaluating myocardial steatosis.
Despite these limitations, Rijzewijk et al. (9) have pro-
ided important translational research that supports the
ndings of animal model data and gives us further insight
nto the underlying pathophysiology of the diabetic heart.
lthough this study does not firmly establish a causative role
or myocardial TG accumulation in diabetic cardiomyopa-
hy, it adds additional supportive evidence, is consistent
ith preliminary evidence from McGavock et al. (6), and
eads us to believe that there is an important role for
dditional studies with interventions aimed at reduction of
yocardial TG content (thiazolidinediones or weight loss/
xercise) and subsequent reassessment of myocardial TG
ontent and parameters of diastolic dysfunction.
eprint requests and correspondence: Dr. Steven P. Marso,
linical Scholar, Mid America Heart Institute, Associate Pro-
essor of Medicine, University of Missouri-Kansas City, 4401
ornall Road, Kansas City, Missouri 64111. E-mail: smarso@
aint-lukes.org.
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